Research Article
Pilot Study on Second-Generation Platelet Concentrates for Treating Chronic Osteomyelitis: A Modern Bio-Regenerative Surgery Approach
Crisci AAim: The supposition is that utilization of advanced fibrin which is enriched with leukocytes with platelets content (A-PRF) for osteomyelitic ulcer in the diabetic limb patients, enables prompt salvage from there debilitating pathology. In this test, the focus was to normalize the application of Platelet Rich-Fibrin in people with osteomyelitic disease, to utilise this 2nd generation platelet paste as a facilitator of effective injury therapy. Methods: The researchers have been using peripheral blood in the production of (A)-PRF (1300 g × 8 min) matrices in 7 subjects (every one of them diagnosed including diabetes), which presented osteomyelitic disease with skin lesions for at least twenty-four weeks. Membranes, combined with the compression-derived sururnatant fluid, have been introduced in through the skin lesion to the bone, post surgeries removal. The development of injuries in the course of time was has been parsed. Results: These seven subjects all tested positive on the “Probe-to-Bone” testing, detected by MRI corticoperiosteal plication and / or areas of cortical-spongeous ulcer-adjacent osseolysis. Presence of Gram + germs was documented in our subjects in 52% of cases. Gram + cocci, as St. Aureus (15.6%), ?-haemolytic Streptococci (12.1%), S. Viridans (7.1%) and Gram - bacillus species including Pseudomonas (10.6%), Proteus (7.8%), Enterobacter (5.7%) were also featured in cultures. Candida Albicans was reported to be present in 2.8%. CBC demonstrated no relevant alterations. As of today, skin wounds have been cured in 6 of the seven subjects processed (one case for more than 5 years) without any evidence of infectivity or repetition. Conclusion: Outcomes observed in our cases recommend which the PRF membranes might be a medical alternative in this challenging disease to treat